International Journal of Drug Delivery Technology
Volume 15, Issue 3

Design, Synthesis and Evaluation of Riboflavin-Isoniazid Conjugate

Wavhale S R*, Shaikh A R

Department of Pharmaceutical Chemistry, MCE’s Allana College of Pharmacy, Pune, affiliated to Savitribai Phule Pune University, Pune-411001, India

Received: 30th Jun, 2025; Revised: 19th Aug, 2025; Accepted: 30th Aug, 2025; Available Online: 25th Sep, 2025

ABSTRACT

The infectious, contagious disease tuberculosis (TB), which is caused by the bacteria Mycobacterium tuberculosis (MT), frequently lasts the entirety of a person's life and results in the formation of tubercles in various parts of the body. This condition is exceedingly difficult to treat because of the complicated connections between different side effects and drug resistance. Along with AIDS and malaria, TB is a strain on healthcare systems in developing countries. Oxidoreductase enzyme was selected for molecular docking. The docking includes the comparison of docking results of Standard ligand that is 6TEV and molecular docking results of Riboflavin- Isoniazid Conjugate. The study used a linker (Riboflavin- Succinic Acid Linker) to create the molecule known as riboflavin-isoniazid conjugate. Melting point and TLC were used to verify the compound's purity. The final compound was confirmed using FTIR, NMR and HRMS study. Conjugate was tested for anti-tubercular activity using the Microplate Almar Blue Assay (MABA).

Keywords: Mycobacterium Tuberculosis, Molecular docking, Riboflavin-Isoniazid Conjugate, Anti-Tubercular activity.

How to cite this article: Wavhale S R, Shaikh A R. Design, Synthesis and Evaluation of Riboflavin-Isoniazid Conjugate. International Journal of Drug Delivery Technology. 2025;15(3):1304-09. doi: 10.25258/ijddt.15.3.51

REFERENCES

  1. Migliori GB, Tiberi S. WHO drug-resistant TB guidelines 2022: what is new? Int J Tuberc Lung Dis. 2022;26(7):590–1. doi:10.5588/ijtld.22.0263.
  2. Migliori GB, Ong CWM, Petrone L, D’Ambrosio L, Centis R, Goletti D. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. 2021;17(3):210079. doi:10.1183/20734735.0079-2021.
  3. Powell DA, Hunt WG. Tuberculosis in children: an update. Adv Pediatr. 2006;53(1):279–322. doi:10.1016/j.yapd.2006.04.014.
  4. Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg. 2017;58(1):E9–12.
  5. Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem. 2012;51:1–16. doi:10.1016/j.ejmech.2012.02.033.
  6. Glickman MS, Jacobs WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. 2001;104(4):477–85. doi:10.1016/S0092-8674(01)00236-7.
  7. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111–20. doi:10.1080/00365540701558698.
  8. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2(1):16076. doi:10.1038/nrdp.2016.76.
  9. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. 2003;83(1–3):91–7. doi:10.1016/S1472-9792(02)00089-6.
  10. Shiratori B, Saitoh H, Ruman U, Zhao J, Chagan-Yasutan H, Usuzawa M, et al. Immunological diagnosis of active and latent TB. In: Cardona P-J, editor. Understanding Tuberculosis - Global Experiences and Innovative Approaches to the Diagnosis. InTech; 2012. doi:10.5772/30900.
  11. Odeh F, Nsairat H, Alshaer W, Ismail MA, Esawi E, Qaqish B, et al. Aptamers chemistry: chemical modifications and conjugation strategies. 2019;25(1):3. doi:10.3390/molecules25010003.
  12. Zhao S, Wang ZP, Wen X, Li S, Wei G, Guo J, et al. Synthesis of vitamin B12-antibiotic conjugates with greatly improved activity against Gram-negative bacteria. Org Lett. 2020;22(16):6632–6. doi:10.1021/acs.orglett.0c02403.
  13. Hafeez A, Saify ZS, Naz A, Yasmin F, Akhtar N. Molecular docking study on the interaction of riboflavin (vitamin B2) and cyanocobalamin (vitamin B12) coenzymes. J Comput Med. 2013;2013:1–5. doi:10.1155/2013/312183.
  14. Wo N, Zhai J. Combinatorial therapeutic drug delivery of riboflavin and dexamethasone for the treatment of keratoconus affected corneas of mice: ex vivo permeation and hemolytic toxicity. Micro Nano Lett. 2021;16(10):492–9. doi:10.1049/mna2.12079.
  15. Dibona-Villanueva L, Fuentealba D. Novel chitosan–riboflavin conjugate with visible light-enhanced antifungal properties against Penicillium digitatum. J Agric Food Chem. 2021;69(3):945–54. doi:10.1021/acs.jafc.0c08154.
  16. Wong PT, Sinniah K, Choi SK. Riboflavin-conjugated multivalent dendrimer platform for cancer-targeted drug and gene delivery. In: Yan B, Zhou H, Gardea-Torresdey JL, editors. Bioactivity of engineered nanoparticles. Singapore: Springer; 2017. p. 145–71. doi:10.1007/978-981-10-5864-6_7.
  17. Thomas TP, Choi SK, Li MH, Kotlyar A, Baker JR. Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery. Bioorg Med Chem Lett. 2010;20(17):5191–4. doi:10.1016/j.bmcl.2010.07.005
  18. Darguzyte M, Drude N, Lammers T, Kiessling F. Riboflavin-targeted drug delivery. Cancers. 2020;12(2):295. doi:10.3390/cancers12020295
  19. Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol. 2012;12(4):695–700. doi:10.1016/j.meegid.2011.08.009
  20. Sankar J, Chauhan A, Singh R, Mahajan D. Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. Frontiers in Pharmacology. 2024 Sep 19;15.